积习难改
发表于 2025-3-25 05:28:16
Book 1987Latest edition discussed. It was decided to keep the layout very simple in order to keep costs to a minimum and make the monographs available in the shortest possible time, thus overcoming a common problem in medical literature: that of the material being outdated even before publication. Umberto Veronesi Chairma
inferno
发表于 2025-3-25 08:28:59
http://reply.papertrans.cn/31/3098/309736/309736_22.png
Slit-Lamp
发表于 2025-3-25 14:46:50
Book 1987Latest editionorientated courses, by promoting new educational initiatives. One of these is the cloister seminars, short meetings intended for highly qualified oncologists and dealing with specific, controversial aspects of clinical practice and research. Another is the institution of permanent study groups, also
植物茂盛
发表于 2025-3-25 17:26:24
http://reply.papertrans.cn/31/3098/309736/309736_24.png
光明正大
发表于 2025-3-25 23:28:37
http://reply.papertrans.cn/31/3098/309736/309736_25.png
grotto
发表于 2025-3-26 02:19:05
Introduction,eting, held in spring 1987 in Venice, on the new premises of the European School of Oncology. I think that the quality of this second volume is even better and I am therefore confident of its success.
oblique
发表于 2025-3-26 05:53:58
Values and Limitations of Current Criteria for Objective Response in Advanced Breast Cancer,te and duration of response. In phase II trials response rate can be used only to estimate the antitumor activity of a specific therapy, whereas in phase III trials it is used as a measure of efficacy based on the expectation that a high rate of response will be translated into a benefit in terms of prolonged time to progression and/or survival.
insurrection
发表于 2025-3-26 11:24:09
Representing Uncertain Knowledgeon of this plateau induces a critical re-evaluation of the overall approach to this disease. This paper will focus mainly on one methodological aspect which is generally underestimated in most reviews.
Immortal
发表于 2025-3-26 13:42:05
http://reply.papertrans.cn/31/3098/309736/309736_29.png
大炮
发表于 2025-3-26 17:42:39
https://doi.org/10.1057/9780230504370te and duration of response. In phase II trials response rate can be used only to estimate the antitumor activity of a specific therapy, whereas in phase III trials it is used as a measure of efficacy based on the expectation that a high rate of response will be translated into a benefit in terms of prolonged time to progression and/or survival.